Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

ÃÀ¸ß÷ÓëÄúÏàÔ¼µÚÈý½ì¹ú¼ÊÉúÎïÒ½Ò©¹¤ÒµÉú³¤´ó»á

2024-09-06
|
»á¼ûÁ¿£º

9ÔÂ12ÈÕ-14ÈÕ£¬£¬£¬£¬£¬£¬µÚÈý½ì¹ú¼ÊÉúÎïÒ½Ò©¹¤ÒµÉú³¤´ó»á½«ÔÚÉϺ£ÄϽ¼±ö¹Ý¾ÙÐС£¡£ ¡£¡£´ó»á½«Í¨¹ýÖ÷Ìⱨ¸æ¡¢Ô²×À¶Ô»°µÈ½»Á÷ÐÎʽ£¬£¬£¬£¬£¬£¬Ì½ÌÖÁ¢ÒìÒ©Îï·¢Ã÷¡¢¿¹Ìå¡¢ÒßÃçÓëÉúÎïÖÎÁÆÐÂÁÆ·¨¡¢¿¹Ö×ÁöÕïÁƵÄвßÂÔºÍм¼Êõ¡¢ÂѰ×Öʼ°¶àëļ¼ÊõÇ°ÑØÓ빤ҵӦÓá¢ÌÇÄò²¡¼°·ÊÅÖ´úл¼²²¡ÕïÖÎм¼ÊõºÍÐÂÁÆ·¨¡¢ÐÂÐÍÃ¸ÖÆ¼ÁµÄ´´ÔìÓ빤ҵ»¯µÈÐÐÒµÈÈÃÅ»°Ìâ¡£¡£ ¡£¡£

ÃÀ¸ß÷×÷Ϊ±¾½ì´ó»áµÄЭ°ìµ¥Î»£¬£¬£¬£¬£¬£¬½«·ºÆðÓ¢²Å¡°É½º£»£»£»£»£»£»á¡±Ô²×ÀÂÛ̳¡£¡£ ¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬ÃÀ¸ß÷ר¼Ò½«ÔÚÖ÷ÂÛ̳¼°×¨Ìâ·ÖÂÛ̳ÉÏ´øÀ´¾«²Ê·ÖÏí£¬£¬£¬£¬£¬£¬Ï£Íûͨ¹ý´Ë´ÎÔ˶¯½øÒ»²½¼ÓÉîÃÀ¸ß÷ÓëÒ½Ò©ÐÐÒµÊ×ÄÔ¡¢×¨¼ÒѧÕß¼äµÄ½»Á÷£¬£¬£¬£¬£¬£¬·ÖÏíÃÀ¸ß÷×îм¼Êõƽ̨ºÍÒ»Ö±¾«½øµÄÁÙ´²Ç°Ñз¢Ð§ÀÍÄÜÁ¦¡£¡£ ¡£¡£

ÎÒÃǽ«È«³ÌÔÚB5ÉèÕ¹£¬£¬£¬£¬£¬£¬³ÏÑûݰÁÙ½»Á÷£¡

µÚÈý½ì¹ú¼ÊÉúÎïÒ½Ò©¹¤ÒµÉú³¤´ó»áչλ.webp

¾Û»áËùÔÚ£ºÉϺ£ÄϽ¼±ö¹Ý£¨·îÏÍÇøÍû԰·8ºÅ£©

ÃÀ¸ß÷Ӣ²Å"ɽº£»£»£»£»£»£»á"Ô²×ÀÂÛ̳

ÃÀ¸ß÷×÷Ϊ±¾½ì´ó»áµÄЭ°ìµ¥Î»£¬£¬£¬£¬£¬£¬½«·ºÆðÓ¢²Å¡°É½º£»£»£»£»£»£»á¡±Ô²×ÀÂÛ̳£¬£¬£¬£¬£¬£¬ÃÀ¸ß÷Ê×ϯ¿ÆÑ§¹ÙÅíË«Çå½ÌÊÚÁªºÏÖ÷³Ö£¬£¬£¬£¬£¬£¬Ê×ϯÉÌÎñ¹Ù²Ì½ðÄȲ©Ê¿³öϯ¶Ô»°£¬£¬£¬£¬£¬£¬²¢Ô¼ÇëÀ´×ÔѧÊõ½ç¡¢¹¤Òµ½çºÍͶ×ʽçµÄ¶¥¼âר¼Ò·ÖÏí¿´·¨ºÍÂÄÀú¡£¡£ ¡£¡£

ʱ¼ä£º9ÔÂ13ÈÕ  08:30-11:50
ËùÔÚ£ºÒ»Â¥·ïÑôÐù

Éϰ볡£¡£ ¡£¡£º08:30-10:15
Ö÷³ÖÈË£ºÐì¾ü£¬£¬£¬£¬£¬£¬ÃÀ¹úBIORICH¹«Ë¾¶­Ê³¤

²Î»á¼Î±ö£º
ÕÅÐ÷Ä£¬£¬£¬£¬£¬£¬ÄÏ·½¿Æ¼¼´óѧƺɽÉúÎïÒ½Ò©Ñо¿ÔºÔº³¤
Ф¹ðɽ£¬£¬£¬£¬£¬£¬ÉîÛÚδÀ¶×ª»¯Ò½Ñ§Ñо¿ÔºÔº³¤
ÕÅÒúÉú£¬£¬£¬£¬£¬£¬ÎÞÎý±´ËþÒ½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾Ê×ϯ¿Æ¼¼¹Ù
÷µÂÊ¢£¬£¬£¬£¬£¬£¬ËÕÖݹú¿ïÒ½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾¶­Ê³¤
Ê¢¾Õ»¨£¬£¬£¬£¬£¬£¬º£Õ飨ÉϺ££©ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾¶­Ê³¤
ÐìºìÑÒ£¬£¬£¬£¬£¬£¬¼ª¶ûÉú»¯£¨ÉϺ££©ÓÐÏÞ¹«Ë¾¶­Ê³¤
ÏÄ Ñô£¬£¬£¬£¬£¬£¬±±¾©Ôªº½×ÊÔ´ºÏ×ÊÈË
ÕŻݱ󣬣¬£¬£¬£¬£¬ÖйúÒ©¿Æ´óѧ½ÌÊÚ
ÇñÇàËÉ£¬£¬£¬£¬£¬£¬¸ßÄÜ×ÊÔ´¸±×ܲÃ
÷Ïþµ¤£¬£¬£¬£¬£¬£¬°Ù°ÂÌ©¼¯ÍŶ­Ê³¤
»ÆÔ¾½ø£¬£¬£¬£¬£¬£¬ÉϺ£èîÃÉÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾¶­Ê³¤
×ÞÖ¾Ñ£¬£¬£¬£¬£¬ÖйúÈ«Çò¿µ½¡Ò©ÎïÑз¢ÖÐÐÄÖ÷ÈÎ

ϰ볡£¡£ ¡£¡£º10:30-11:50
Ö÷³ÖÈË£ºÅíË«Ç壬£¬£¬£¬£¬£¬ÃÀ¸ß÷Ê×ϯ¿ÆÑ§¹Ù

²Î»á¼Î±ö£º
×ÞÁéÁú£¬£¬£¬£¬£¬£¬ËÕÖÝ¿µÎ¬Ñ¶ÉúÎï¼¼Êõ¶­Ê³¤
Âí¿ª¹ú£¬£¬£¬£¬£¬£¬ÀÊ»ªÖÆÒ©CEO£»£»£»£»£»£»Î¬ÑÇÉúÎï¸ß¼¶¸±×ܲÃ
Íõ ´Ô£¬£¬£¬£¬£¬£¬Âõ½Üת»¯Ò½Ñ§Ñо¿£¨ËÕÖÝ£©ÓÐÏÞ¹«Ë¾¸ß¼¶¸±×ܲÃ
²Ì½ðÄÈ£¬£¬£¬£¬£¬£¬ÉϺ£ÃÀ¸ß÷ÉúÎïÒ½Ò©ÓÐÏÞ¹«Ë¾Ê×ϯÉÌÎñ¹Ù
ÁõÃÏÔª£¬£¬£¬£¬£¬£¬Á¢ÔªÉúÎïÒ½Ò©¼¼ÊõÓÐÏÞ¹«Ë¾£¬£¬£¬£¬£¬£¬¶­Ê³¤¼æCEO
κ¼ÌÒµ£¬£¬£¬£¬£¬£¬ËÕÖÝΩÓÓ»ùÒòÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾¶­Ê³¤
Ç® êÍ£¬£¬£¬£¬£¬£¬½­ËÕ´óѧҽѧԺ½ÌÊÚ
Áº Íþ£¬£¬£¬£¬£¬£¬ÉϺ£ÓòÔÆÒ½ÁÆ¿µ½¡¿Æ¼¼ÓÐÏÞ¹«Ë¾Ê×´´ÈË¡¢CEO
ÂíÐËÔª£¬£¬£¬£¬£¬£¬»ª¶«Àí¹¤´óѧ½ÌÊÚ
ÕÅÑ϶¬£¬£¬£¬£¬£¬£¬ÉîÛÚ¿ªÔÃÉúÃü¿Æ¼¼ÓÐÏÞ¹«Ë¾Ê×ϯ¿ÆÑ§¹Ù
³Âº£Ï¼£¬£¬£¬£¬£¬£¬Ìì½ò´óѧҩÎï¿ÆÑ§Óë¼¼ÊõѧԺ½ÌÊÚ
ÑÌΣ¬£¬£¬£¬£¬£¬ÄÏ·½¿Æ¼¼´óѧϸ°ûÓë»ùÒòÖÎÁÆÑо¿ÖÐÐĽÌÊÚ£»£»£»£»£»£»Èðôà°ÂÄÉ£¨ÉîÛÚ£©ÉúÎïÒ½Ò©ÓÐÏÞ¹«Ë¾Ê×´´ÈË

ÃÀ¸ß÷ר¼Ò¼´½«·ÖÏí

ÅíË«Çå  ½ÌÊÚ.webp

ÅíË«Çå ½ÌÊÚ ÃÀ¸ß÷Ê×ϯ¿ÆÑ§¹Ù

±±¾©´óѧԤ·Àҽѧ²©Ê¿ºó¡¢Öйú¶¾Àíѧ»á¸±Àíʳ¤¡¢ÃÀ¹úÃÜÎ÷¸ùÖÝÁ¢´óѧҩÀíѧ²©Ê¿ºó¡£¡£ ¡£¡£ºã¾Ã´ÓÊÂÐÂÒ©´´ÔìÁÙ´²Ç°Ñо¿£¬£¬£¬£¬£¬£¬¼ç¸ºGLP¼¼Êõƽ̨½¨Éè¡£¡£ ¡£¡£½ÒÏþ¿ÆÑÐÂÛÎÄ300ÓàÆª£¨SCIÂÛÎÄ100ÓàÆª£©£¬£¬£¬£¬£¬£¬Ö÷±à²Î±à׍ָ13²¿¡£¡£ ¡£¡£»£»£»£»£»£»ñÊ¡²¿¼¶¿Æ¼¼½±12Ï£¬£¬£¬£¬£¬»ñÖйú¿ÆÐ­¡°ÌìÏÂÓÅÒì¿Æ¼¼ÊÂÇéÕß¡±ÉùÓþ³Æºô¡¢Öйú¶¾ÀíѧÓÅÒìТ˳½±¡£¡£ ¡£¡£×÷Óý˶ʿ¡¢²©Ê¿¼°²©Ê¿ºó90¶àÃû¡£¡£ ¡£¡£¼æÈÎʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÐÂÒ©ÉóÆÀר¼Ò¡¢Ò½ÁÆÆ÷еÉóÆÀר¼Ò¡¢»·±£²¿ÐÂÎïÖÊÉóÆÀר¼Ò¼°ETAP¸±Ö÷±àµÈѧÊõÖ°Îñ¡£¡£ ¡£¡£

¶Ô»°Ö÷Ì⣺The Future of Biopharma: Navigating Innovation, Regulation, and Global Collaboration
ËùÔÚ£º  Ò»Â¥»ª²ýÌü Ö÷ÂÛ̳
ʱ¼ä£º 9ÔÂ12ÈÕ 12:00-12:30

Íõµ¤  ²©Ê¿.webp

Íõµ¤ ²©Ê¿ ÃÀ¸ß÷ÐÂÒ©×¢²á²¿×ܼà&ÖÆ¼Á²¿¸ß¼¶Ö÷ÈÎ

Íõµ¤£¬£¬£¬£¬£¬£¬ÉòÑôÒ©¿Æ´óѧ±¾¿Æ£¬£¬£¬£¬£¬£¬ÉϺ£½»Í¨´óѧ˶ʿ£¬£¬£¬£¬£¬£¬¸´µ©´óѧ²©Ê¿£¬£¬£¬£¬£¬£¬ÔÚÒ©ÆóÓÐÊ®ÓàÄêÑз¢ÂÄÀú£¬£¬£¬£¬£¬£¬ÔøÏòµ¼ÍŶÓ×éÖ¯¹ý¶à¸öÏîÄ¿µÄ×¢²áÉ걨£¬£¬£¬£¬£¬£¬ÊìϤÐÂÒ©CMCºÍÁÙ´²Ç°ÆÀ¼ÛÀú³Ì£¬£¬£¬£¬£¬£¬ÒÔ¼°Ò©ÎïµÄÁÙ´²ÆÀ¼ÛÀú³Ì£¬£¬£¬£¬£¬£¬ÄÜÔÚÁ¢ÒìÒ©×¢²áÉ걨²ßÂÔÒÔ¼°Ò©Î↑·¢Ê±´ú£¬£¬£¬£¬£¬£¬Ìṩ¸üºÃµÄ¹æÔòºÍ¼¼ÊõÖ§³Ö¡£¡£ ¡£¡£

·ÖÏíÖ÷Ì⣺BL-602, A Cyclophilin Inhibitor, Reduces Fibrosis and Proteinuria in Chronic Kidney Disease
ËùÔÚ£º  Ò»Â¥»ª²ýÌü Ö÷ÂÛ̳
ʱ¼ä£º 9ÔÂ12ÈÕ 11:35-11:55

Ô¬ÔÆÔÆ  ²©Ê¿.webp

Ô¬ÔÆÔÆ ²©Ê¿ ÃÀ¸ß÷ҩЧ²¿ÏîĿ˾Àí

ÉϺ£ÖÐÒ½Ò©´óѧ²©Ê¿£¬£¬£¬£¬£¬£¬Ö÷Òª´ÓÊ·ÇÖ×ÁöÒ©ÎïµÄÁÙ´²Ç°ÌåÄÚҩЧѧÆÀ¼ÛÊÂÇ飬£¬£¬£¬£¬£¬Ñо¿ÄÚÈݰüÀ¨´úлÐÔ¼²²¡¡¢ÄÔ×äÖС¢¾«Éñ¼²²¡ÒÔ¼°Ñ×Ö¢ÃâÒßÀ༲²¡µÄ¶¯ÎïÌåÄÚҩЧѧ¼°Ò©Àí»úÖÆÑо¿¡£¡£ ¡£¡£ÏÖÔÚÔÚÃÀ¸ß÷Ñз¢Æ½Ì¨¼ÓÈë²¢Íê³É°ÙÓàÏîÏà¹ØÐÂÒ©Ñз¢ÏîÄ¿£¬£¬£¬£¬£¬£¬ËùÈÏÕæµÄ¶à¸öÏîÄ¿ÒÑÍê³Éº£ÄÚÍâINDÉ걨¡£¡£ ¡£¡£

·ÖÏíÖ÷Ì⣺Animal Models of Human Diseases and the Application in Pharmacodynamic Studies
ËùÔÚ£º  Ò»Â¥¾Û»áÊÒ5B  IDDST02-¼²²¡Ä£×ÓÓëÓ¦ÓÃ
ʱ¼ä£º 9ÔÂ12ÈÕ 14:05-14:30

´ó»áÏêÇé¸ÅÀÀ

µÚÈý½ì¹ú¼ÊÉúÎïÒ½Ò©¹¤ÒµÉú³¤´ó»áչλ´ó¾Û»áÌâ.webp

ÁªÏµÃÀ¸ß÷

ÈçÄúÏ£ÍûÔÚÏÖ³¡ÓëÃÀ¸ß÷ר¼ÒÅöÃæ
»¶Ó­ÁªÏµÃÀ¸ß÷ԤԼ°²ÅÅ

ɨÂëÔÚÏßÁªÏµ.webp

ɨÂëÔÚÏßÁªÏµ
ÁªÏµÓÊÏ䣺marketing@medicilon.com.cn

Ïà¹ØÐÂÎÅ
ÉúÎïÒ½Ò©¹¤Òµ²½ÈëÉú³¤¿ì³µµÀÒýÖÚ¶àͶ×ÊÕß¹Ø×¢
2017-11-27
Ò½Ò©Ñз¢ÊÇÒ»¸öµä·¶µÄÖÜÆÚ³¤¡¢Í¶×Ê´óµÄÔ˶¯£¬£¬£¬£¬£¬£¬¾­ÓÉǰЩÄêµÄÖØµãͶÈëºÍ¶¦Á¦´ó¾Ù¹¥¹Ø£¬£¬£¬£¬£¬£¬º£ÄÚÖØµãÒ©ÆóµÄÒ»ÅúÐÂÒ©¼´½«½øÈë¡°ÊÕ»ñÆÚ¡±¡£¡£ ¡£¡£ÒÔA¹ÉΪÀý£¬£¬£¬£¬£¬£¬¸´ÐÇÒ½Ò©ÌåÏÖ£¬£¬£¬£¬£¬£¬ÏÖÔÚÔÚÖ×Áö¡¢×ÔÉíÃâÒßÐÔ¼²²¡·½Ã棬£¬£¬£¬£¬£¬ÓÐ8¸ö²úÆ·»ñ11¸öÈ«ÇòÁÙ´²Åú¼þ¡£¡£ ¡£¡£ºãÈðÒ½Ò©²Æ±¨ÏÔʾ£¬£¬£¬£¬£¬£¬½ñÄêÉϰëÄ깫˾ÀÛ¼ÆÍ¶ÈëÑз¢×ʽð7.8ÒÚÔª£¬£¬£¬£¬£¬£¬Í¬±ÈÔöÌí60%£¬£¬£¬£¬£¬£¬»ù±¾ÐγÉÁËÿÄê¶¼ÓÐÁ¢ÒìÒ©ÉêÇëÁÙ´²µÄÁ¼ÐÔÉú³¤Ì¬ÊÆ¡£¡£ ¡£¡£
ÉúÎïÒ½Ò©¹¤ÒµÊг¡±¨¸æ£ºÒ½Ò©ÉÏÊй«Ë¾Òµ¼¨ÔöÌíÌ¬ÊÆÓÅÒì
2016-09-19
2016ÄêÉϰëÄêÒ½Ò©ÐÐÒµÓªÊÕͬ±ÈÔöÌí10%£¬£¬£¬£¬£¬£¬Î»¾Ó¹¤Òµ¸÷ÐÐÒµÔöËÙǰÏߣ¬£¬£¬£¬£¬£¬ÊÕÈëÔöËÙÓÐËùÆóÎÈ¡£¡£ ¡£¡£ÐÐҵëÀûÂʺÍÖ÷ÓªÓªÒµÀûÈóÂÊͬ±È¾ùÓÐËùÌá¸ß£¬£¬£¬£¬£¬£¬·´Ó¦ÁËÐÐÒµ½Ï¸ßµÄÓ¯ÀûÄÜÁ¦¡£¡£ ¡£¡£
ÉϺ£ÊÐÉúÎïÒ½Ò©¹¤ÒµÉú³¤Ðж¯ÍýÏ루2014-2017Ä꣩
2015-08-04
ÉúÎïÖÆÒ©£º¶¦Á¦´ó¾ÙÉú³¤¿¹Ö×Áö¡¢¿¹Àà·çʪµÈ¿¹ÌåÒ©Î£¬£¬£¬£¬£¬¼ÓËÙÖÎÁÆÐÔ»ùÒò¹¤³ÌÒßÃçµÄÑз¢£¬£¬£¬£¬£¬£¬Æð¾¢Íƶ¯¿¹Ö×ÁöºÍÖÎÁÆÐÄË¥µÈÖØ×éϸ°ûÒò×ÓÒ©ÎïµÄ¹¤Òµ»¯£¬£¬£¬£¬£¬£¬Ì½Ë÷Ö§³ÖºËËáÒ©Îï¡¢¸Éϸ°ûµÈÇ°ÑØ¼¼ÊõÁ¢Ò죬£¬£¬£¬£¬£¬·¢¶¯ÉϺ£ÉúÎïÖÆÒ©¹¤ÒµµÄ¿ìËÙÉú³¤£¬£¬£¬£¬£¬£¬µ½2017Äêµ×£¬£¬£¬£¬£¬£¬ÊµÏÖÖ÷ÓªÓªÒµÊÕÈë180ÒÚÔª¡£¡£ ¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿